Upexi Inc (UPXI) reported QQ3 2024 results that highlighted a meaningful top-line contraction and deteriorating profitability, underscoring a stretched liquidity position as the company continues its transition in the Health & Wellness, Pet, and Beauty products segments. Revenue for the quarter was 14.445 million, down 40.36% year-over-year and 18.82% quarter-over-quarter, with gross margins approximately 20% (gross profit of 2.883 million on 11.562 million cost of revenue). The company posted an operating loss of 4.937 million and a net loss of 4.119 million, with basic and diluted EPS of -3.97. EBITDA was negative at -3.806 million, and the EBITDARatio stood at -0.263. This combination of lower revenue, persistent operating leverage, and high operating expenses driven a worsening cash burn; operating cash flow registered -0.690 million and free cash flow was -0.981 million for the quarter. The balance sheet shows total assets of 56.507 million against total liabilities of 34.451 million and stockholders’ equity of 22.056 million, with retained earnings deeply negative at -31.114 million and goodwill/intangible assets totaling roughly 20.317 million. Liquidity metrics reflect a precarious position: cash and cash equivalents of 0.498 million, current ratio 0.696, quick ratio 0.332, and cash ratio 0.0206, while short-term debt peaks at 18.264 million and total debt at 28.523 million. Net debt stands at approximately 28.024 million. The quarter’s dynamics signal that without meaningful top-line stabilization or margin improvement, debt-servicing capacity and liquidity remain stressed. Management commentary is not provided in the supplied transcript data, so quotes and call-specific guidance could not be incorporated directly. Overall, the QQ3 2024 results imply a high-risk near-term investment profile with potential upside if the company executes on cost discipline, product mix optimization, and revenue resilience.”, 0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0:0,